RESUMO
Purpose: To use a medical claim database to investigate medical costs and treatment patterns among patients newly starting glaucoma care.Subjects and methods: Subjects registered in the Japan Medical Database Center (JMDC) from January 2005 to March 2016 who were newly diagnosed with glaucoma, started glaucoma treatment, and had treatment records covering more than five years were included in the analysis. All direct medical costs were collected for a period of up to ten years. Factors affecting medical costs were analyzed. Changes in hypotensive eyedrops and choices related to glaucoma surgery were also analyzed.Results: Out of approximately 1.42 million subjects, 2,393 satisfied the inclusion and exclusion criteria. The average total medical cost incurred per patient over a period of ten years was US$9,030, including US$1,214 during the initial year. The proportion of the total cost represented by the cost of hypotensive eyedrops increased from 5.2% to 10.6% over the ten-year period. Medical costs were higher in patients younger than ten years old than in patients of all other age groups. The number of ocular hypotensive eyedrops increased from 0.9 to 1.5 over the ten-year period. Medical costs were higher for subjects with secondary glaucoma than for other subjects. Sixty-three patients underwent trabeculotomy or trabeculectomy, and trabeculectomy was the preferred choice in later years.Conclusions: The total direct medical cost associated with glaucoma was US$9,030 for the first ten years. Drug costs gradually increased with treatment duration and patient age and varied by glaucoma type.
Assuntos
Anti-Hipertensivos/economia , Cirurgia Filtrante/economia , Glaucoma/economia , Custos de Cuidados de Saúde/estatística & dados numéricos , Terapia a Laser/economia , Adulto , Anti-Hipertensivos/uso terapêutico , Bases de Dados Factuais , Custos de Medicamentos , Feminino , Glaucoma/terapia , Humanos , Pressão Intraocular/efeitos dos fármacos , Japão , Masculino , Programas de Assistência Gerenciada , Pessoa de Meia-Idade , Soluções OftálmicasRESUMO
PURPOSE: Two of the hurdles that are facing ophthalmologists in developing countries are scarcity of resources and patient follow-up. Deep sclerectomy (DS) has proven less costly and more effective than topical therapies and has a more favorable safety profile than trabeculectomy. The main factors preventing its use in developing countries are the need to perform laser goniopuncture in 40-80% of cases to maintain filtration and the risk of postoperative iris incarceration. The purpose of this study is to assess the efficacy and safety profile in advanced open-angle glaucoma of a relatively new surgical technique designed to overcome this limitation: penetrating DS. SETTING: This was an investigator-initiated, prospective, interventional study, conducted at a single ophthalmology center in Kinshasa, Congo. The study was conducted in full compliance with the Declaration of Helsinki. METHODS: Fifty-one eyes (34 patients) with uncontrolled advanced primary open-angle glaucoma (visual field mean deviation<-10 dBs) were enrolled between October 2012 and June 2016. Age, gender, comorbidities (hypertension/diabetes), best-corrected visual acuity, topical medications, medicated and unmedicated intraocular pressure (IOP) were recorded. All patients underwent penetrating DS, during which, following standard dissection of the scleral flaps, the anterior chamber was penetrated through the trabeculo-Descemet membrane and an iridectomy was performed. Patients attended postoperative appointments at months 1, 3, 6 and 12. Surgical success was defined as a 20% reduction of IOP from baseline in conjunction with a 12-month unmedicated IOP≤12mmHg. RESULTS: The mean age was 64.5±14.0 years (44.1% female, 100% African). Mean IOP decreased from 20.2±6.1 (medicated) and 30.7±9.8mmHg (unmedicated) preoperatively to 12.1±4.1 at 12 months. Concomitantly, the number of topical medications decreased from 1.5±0.7 to 0.0. Complete surgical success was achieved in 64.7%. Four eyes (7.8%) were considered surgical failures due to uncontrolled IOP. None of the eyes lost light perception or required additional surgery. A significant association between surgical failure and hypertension was observed (HR=1.49; P=0.008). There were no intraoperative complications. Postoperatively, 4 bleb encapsulations (7.8%) and 1 iris incarceration (2%) were observed. CONCLUSIONS: The present study demonstrates that penetrating DS achieved similar efficacy and safety results to traditional non-penetrating DS. In addition, it showed a lower potential for intraoperative complications, which might be associated with a more benign surgical learning curve. Finally, the rates of serious postoperative complications (iris incarceration, choroidal effusion and hypotony) were significantly lower than in DS and trabeculectomy, and this technique does not require subsequent Nd: YAG laser goniopuncture to maintain filtration, making frequent follow-up visits less critical. In view of these findings, perforating deep sclerectomy could offer a viable option for glaucoma management in developing countries as well as worldwide.
Assuntos
Glaucoma de Ângulo Aberto/cirurgia , Esclerostomia/métodos , Idoso , República Democrática do Congo , Países em Desenvolvimento , Progressão da Doença , Feminino , Cirurgia Filtrante/economia , Cirurgia Filtrante/métodos , Seguimentos , Glaucoma de Ângulo Aberto/economia , Glaucoma de Ângulo Aberto/patologia , Humanos , Pressão Intraocular , Masculino , Pessoa de Meia-Idade , Complicações Pós-Operatórias/etiologia , Pobreza/economia , Esclera/patologia , Esclera/cirurgia , Esclerostomia/efeitos adversos , Esclerostomia/economia , Trabeculectomia/efeitos adversos , Trabeculectomia/economia , Trabeculectomia/métodosRESUMO
Acute primary angle closure requires emergency management that involves a rapid lowering of the intraocular pressure and resolution of relative pupil block - the most common mechanism of angle closure. Emergency strategies for lowering intraocular pressure include medical treatment and argon laser peripheral iridoplasty. Anterior chamber paracentesis and diode laser transcleral cyclophotocoagulation may be considered in special situations. Relative pupil block can be relieved by peripheral laser iridotomy and primary lens extraction; the latter is a more effective treatment according to the results of clinical trials. However, primary lens extraction can be technically demanding in the acute setting. Peripheral laser iridotomy has a role in relieving pupil block and should also be considered in most cases. Lens extraction may be combined with procedures such as goniosynechialysis, trabeculectomy or endoscopic cyclophotocoagulation. In this review, we aim to discuss the available evidence regarding the different treatment modalities. We also discuss the economic consideration, including cost-effectiveness and life expectancy, in the management of acute primary angle closure.
Assuntos
Gerenciamento Clínico , Cirurgia Filtrante/métodos , Glaucoma de Ângulo Fechado , Custos de Cuidados de Saúde , Pressão Intraocular/fisiologia , Guias de Prática Clínica como Assunto , Doença Aguda , Cirurgia Filtrante/economia , Glaucoma de Ângulo Fechado/economia , Glaucoma de Ângulo Fechado/fisiopatologia , Glaucoma de Ângulo Fechado/cirurgia , HumanosRESUMO
BACKGROUND: Glaucoma is a condition that causes progressive damage to the optic nerve, which can lead to visual impairment and irreversible blindness. There is a spectrum of current treatments for glaucoma that aim to reduce intraocular pressure (IOP), including pharmacotherapy (eye drops), laser therapy, and the more invasive option of filtration surgery. A new class of treatments called minimally invasive glaucoma surgery (MIGS) may reduce IOP and offer a better safety profile than more invasive procedures. We conducted a budget impact analysis of MIGS for adults with glaucoma from the perspective of the Ontario Ministry of Health and Long-Term Care. We also conducted interviews with people with glaucoma and family members of people with glaucoma to determine patient preferences and values surrounding glaucoma and its treatment options, including MIGS. We completed this work to complement a health technology assessment conducted in collaboration with the Canadian Agency for Drugs and Technologies in Health (CADTH). METHODS: We analyzed the budget impact of publicly funding MIGS in adults with glaucoma in Ontario. We derived costs from the collaborative health technology assessment.1 We assumed MIGS may be used in three subgroups: (1) MIGS in combination with cataract surgery as a replacement for cataract surgery alone in people with mild to moderate glaucoma; (2) MIGS alone as a replacement for other glaucoma treatments in people with mild to moderate glaucoma; and (3) MIGS (alone or in combination with cataract surgery) to replace filtration surgery (alone or in combination with cataract surgery) in people with advanced to severe glaucoma. We estimated the budget impact over 5 years for two possible uptake scenarios: a slow rate of uptake and a fast rate of uptake. To contextualize the lived experience of glaucoma and treatments for glaucoma, we also interviewed people with glaucoma and family members of people with glaucoma, some of whom had experience with surgical procedures such as MIGS and some of whom did not. RESULTS: Assuming a slow uptake scenario, the annual budget impact of publicly funding MIGS in Ontario over the next 5 years ranges from $1 million in year 1 to $18 million in year 5. Assuming a fast uptake scenario, the annual budget impact of publicly funding MIGS in Ontario over the next 5 years ranges from $6 million in year 1 to $70 million in year 5. The budget impact varies depending on the proportion of people in each of the three subgroups described above. Introducing a new MIGS billing code may reduce the overall expenditures. Interview participants felt that less invasive surgical procedures, such as MIGS, could control glaucoma progression with minimal side effects and recovery time needed. CONCLUSIONS: We estimate that publicly funding MIGS in Ontario would result in additional costs over the next 5 years; however, this may depend on the populations using MIGS and if uptake is restricted or controlled. For the people with glaucoma we spoke with, avoiding blindness was their paramount concern, and MIGS was perceived as an effective treatment option with minimal side effects and recovery time required.
Assuntos
Financiamento Governamental/economia , Glaucoma/cirurgia , Procedimentos Cirúrgicos Minimamente Invasivos/economia , Procedimentos Cirúrgicos Oftalmológicos/métodos , Preferência do Paciente , Orçamentos , Análise Custo-Benefício , Cirurgia Filtrante/economia , Glaucoma/economia , Humanos , Procedimentos Cirúrgicos Minimamente Invasivos/métodos , Procedimentos Cirúrgicos Oftalmológicos/economia , Qualidade de VidaRESUMO
BACKGROUND: The main objectives of this analysis were to assess the treatment costs and to identify major cost drivers and factors predicting direct costs in German patients with ocular hypertension (OHT) or primary open-angle glaucoma (POAG). METHODS: This non-interventional cross-sectional study was conducted in two university hospitals and 13 ophthalmology practices in Germany regions (Bavaria, Rhineland-Palatinate, North Rhine-Westphalia, Hamburg and Mecklenburg-Western Pomerania) between May 2009 and January 2010 to assess resource utilisation in patients with OHT (ICD-10: 40.0) or POAG (ICD-10: 40.1) at early, moderate or advanced stages, according to the European Glaucoma Society classification Guidelines. Treatment patterns and direct costs were evaluated retrospectively for 5 years. Resource utilisation data (medication, hospitalisation, outpatient surgery, visits to ophthalmologists) were abstracted from the charts, and unit costs were applied to estimate direct costs per year (in Euros, 2009), calculated from the perspective of the statutory health insurance in Germany (Gesetzliche Krankenversicherung). Factors predicting costs were assessed in multivariate regression analysis. RESULTS: One hundred and fifty-four patients (17.5% OHT, 27.9% early, 22.7% moderate, and 31.8% advanced POAG), on average 67 years old (SD 11) were included in the study. Average total annual direct costs per patient for OHT were
Assuntos
Glaucoma de Ângulo Aberto/economia , Glaucoma de Ângulo Aberto/terapia , Custos de Cuidados de Saúde , Oftalmologia/economia , Idoso , Assistência Ambulatorial/economia , Anti-Hipertensivos/economia , Anti-Hipertensivos/uso terapêutico , Comorbidade , Estudos Transversais , Progressão da Doença , Custos de Medicamentos , Feminino , Cirurgia Filtrante/economia , Cirurgia Filtrante/métodos , Alemanha , Glaucoma de Ângulo Aberto/classificação , Glaucoma de Ângulo Aberto/diagnóstico , Recursos em Saúde/estatística & dados numéricos , Hospitalização/economia , Humanos , Pressão Intraocular , Masculino , Pessoa de Meia-Idade , Hipertensão Ocular/diagnóstico , Hipertensão Ocular/economia , Hipertensão Ocular/terapia , Estudos Retrospectivos , Tonometria Ocular , Resultado do TratamentoRESUMO
PURPOSE: To describe the costs and providers of glaucoma treatment in Denmark. METHODS: Analyses were based on National Register data. Glaucoma/OHT patients were identified by their first prescription for glaucoma medication (ATC-codes) in the Danish Register of Medicinal Product Statistics 2002-2007. Patients had used no glaucoma medication for 6 months. Data for 2007 were sampled cross-sectionally for a budgetary analysis of glaucoma (ICD10 code) medication and services consumed in the primary and secondary health care services. Patients were categorized according to their number of treatment changes. RESULTS: The Danish annual incidence rate of glaucoma was estimated at 1.2 per 1000 adult persons. Thirty-seven per cent of patients (men 44%, mean age 68 years; women 56%, mean age 71 years) persisted with their initial treatment regimen, 21% had changed to a second regimen, and 43% had experienced ≥ 3 regimens. Treatment costs increased with the number of sequential regimens. Annual glaucoma costs (health care sector perspective) were 305 for patients under their initial regimen, increasing to 740 with ≥ 3 regimens. Drug costs accounted for 57% of total cost. CONCLUSIONS: Drugs represented the major cost of glaucoma, and those costs increased, obviously, with the number of treatment changes.
Assuntos
Glaucoma/economia , Custos de Cuidados de Saúde/estatística & dados numéricos , Idoso , Anti-Hipertensivos/economia , Dinamarca/epidemiologia , Feminino , Cirurgia Filtrante/economia , Glaucoma/terapia , Gastos em Saúde , Humanos , Incidência , Masculino , Sistema de RegistrosRESUMO
PURPOSE: Due to increasing cost pressure in the public health system treatments and their costs are highly relevant in the therapy for chronic diseases such as glaucoma. In the era of diagnosis-related group (DRG) reimbursement, new interventions need to prove not only their safety and effectiveness but also their cost-utility. Canaloplasty as a new interventional surgery is compared to trabeculectomy (TE) by means of a cost and effort analysis. METHODS: In this retrospective, consecutive case series patients were compared as follows: group I, 21 eyes of 21 patients undergoing canaloplasty from 2009 on and group II, 48 eyes of 42 patients, who were treated with TE with mitomycin C (MMC) from 2001 to 2004 and had intensified postoperative care. Data regarding demography, duration of hospitalisation, duration of surgery, surgical complications and interventions, and pre- and post-operative IOP were analysed within the first 6 months post operation. RESULTS: In group I mean duration of hospitalisation was 5.3 ± 0.8 days (d) and in group II 10.7 ± 2.8 d. Duration of surgery was 77 ± 14 min in group I and in group II 48 ± 11 min. On average 2.8 ± 1.0 visits were needed during follow-up in group I and 6 ± 1.5 visits in group II. The mean preoperative IOP of 28.75 ± 9.6 mmHg was lowered to 12.8 ± 3.3 mmHg after six months in group I and in group II from 34.5 ± 13.4 mmHg to 10.3 ± 4.5 mmHg. In group I, a total of 4 interventions were seen within the first six months without re-admission. In group II 107 interventions and eleven re-admissions were necessary. Mean costs for hospitalisation amount to 821.50 in group I and 1658.50 in group II. Overall expenses were 2379.62 for canaloplasty and 2733.61 for TE. CONCLUSION: Both interventions could effectively control IOP. However, trabeculectomy requires a longer hospitalisation, has higher re-admission rates and needs more frequent postoperative controls, which makes TE more costly and time-consuming than canaloplasty.
Assuntos
Cirurgia Filtrante/economia , Cirurgia Filtrante/métodos , Programas Nacionais de Saúde/economia , Próteses e Implantes/economia , Trabeculectomia/economia , Trabeculectomia/métodos , Idoso , Análise Custo-Benefício/métodos , Feminino , Seguimentos , Alemanha , Humanos , Tempo de Internação/economia , Masculino , Pessoa de Meia-Idade , Readmissão do Paciente/economia , Cuidados Pós-Operatórios/economia , Mecanismo de Reembolso/economia , Reoperação/economia , Estudos RetrospectivosRESUMO
PURPOSE OF REVIEW: This review evaluates the last 18-month literature related to costs and glaucoma. The emphasis is to look at evidence as a big picture and evaluate the critical points and challenges in methodology, current knowledge and future research. RECENT FINDINGS: On the basis of simulation models, treating glaucoma appears to be cost-effective compared with no treatment. The results of the simulation models are, however, not consistent regarding when to treat ocular hypertension and when comparing different therapeutic interventions. Most models simulated starting treatment with prostaglandins compared with other medications, whereas one study simulated also initial laser therapy which appeared to be cost saving compared with medical therapy. The models utilized input data both from randomized controlled trials (ideal outcomes) and observational studies (with incomplete and selective reporting). Models suffer from unreliability of data, for example data from randomized diagnostic trials, empirical data of utility values and glaucoma-induced visual disability are limited. SUMMARY: As the number of economic evaluations increases, the interpretation and evaluation of their extensive reporting appears very challenging. The published studies highlight the range of uncertainties due to the shortages of our current knowledge and evidence. There is a need for reliable and 'realistic' data for economic evaluations, preferably data from pragmatic randomized trials of 'usual patients'. Similar to emphasizing the cost-effectiveness of care, there is a need to evaluate the expected payback and cost-effectiveness of research interventions. However, even high-quality evidence cannot help our patients if we do not adopt cost-effective interventions.
Assuntos
Anti-Hipertensivos/economia , Efeitos Psicossociais da Doença , Técnicas de Diagnóstico Oftalmológico/economia , Cirurgia Filtrante/economia , Glaucoma/economia , Custos de Cuidados de Saúde , Análise Custo-Benefício , Glaucoma/diagnóstico , Glaucoma/terapia , Recursos em Saúde/economia , Humanos , Modelos EconômicosRESUMO
OBJECTIVE: To identify payments and changes in payments for glaucoma surgical procedures among Medicare beneficiaries in the United States and to evaluate trends in costs based on the types of procedures being performed. DESIGN: Retrospective analysis using 1997 through 2006 Part B Medicare Beneficiary Encrypted Files. The annual number of claims and payments for glaucoma surgical procedures were calculated, as were the rates per 100 000 beneficiaries. RESULTS: Overall, there were decreases in both the number of glaucoma surgical procedures and the amount of annual payments from 1997 to 2001 but an increase in the number of procedures in the following years. Trends in claims and payments vary according to procedure. Average payments for trabeculectomies decreased over time, while annual payments for cyclophotocoagulation and shunt-related procedures have increased. After an initial decline, there was a substantial increase in the number of trabeculoplasties in conjunction with advancements in technology and a change in the global period for reimbursement. Patterns of surgery rates were similar to volume of surgical procedures. CONCLUSIONS: Findings suggest that while the overall number of glaucoma surgical procedures is increasing, payments have been decreasing. Clinical and technological advancements and reimbursement decisions may influence surgeons' preferences and, therefore, costs to Medicare.
Assuntos
Cirurgia Filtrante/economia , Glaucoma/economia , Gastos em Saúde/tendências , Medicare Part B/economia , Centers for Medicare and Medicaid Services, U.S./estatística & dados numéricos , Current Procedural Terminology , Glaucoma/cirurgia , Custos de Cuidados de Saúde , Pesquisa sobre Serviços de Saúde , Humanos , Iridectomia/economia , Iris/cirurgia , Fotocoagulação a Laser/economia , Padrões de Prática Médica/economia , Estudos Retrospectivos , Estados UnidosAssuntos
Anti-Hipertensivos/economia , Técnicas de Diagnóstico Oftalmológico/economia , Cirurgia Filtrante/economia , Glaucoma de Ângulo Aberto , Custos de Cuidados de Saúde , Transtornos da Visão/prevenção & controle , Anti-Hipertensivos/uso terapêutico , Ensaios Clínicos como Assunto , Simulação por Computador , Análise Custo-Benefício , Avaliação da Deficiência , Progressão da Doença , Glaucoma de Ângulo Aberto/diagnóstico , Glaucoma de Ângulo Aberto/economia , Glaucoma de Ângulo Aberto/terapia , Pesquisa sobre Serviços de Saúde , Humanos , Incidência , Modelos Biológicos , Casas de Saúde/economia , Consultórios Médicos , Anos de Vida Ajustados por Qualidade de Vida , Estados Unidos , Transtornos da Visão/diagnóstico , Campos VisuaisRESUMO
OBJECTIVE: To estimate the incremental cost-effectiveness of routine glaucoma assessment and treatment under current eye care visit and treatment patterns and different levels of treatment effectiveness (from randomized trials). DESIGN: We compared the costs and benefits of routine glaucoma assessment and treatment compared with no treatment using conservative and optimistic assumptions regarding treatment efficacy and including and excluding prediagnostic assessment costs. PARTICIPANTS AND CONTROLS: Computer simulation of 20 million people followed from age 50 years to death or age 100 years. METHODS: With the use of a computer model, we simulated glaucoma incidence, natural progression, diagnosis, and treatment. We defined glaucoma incidence conservatively as a mean deviation of -4 decibels (dB) on visual field testing in either eye for all diagnoses to be both clinically meaningful and unambiguous. We simulated the annual probability of subsequent progression and the quantity of visual field lost when progression occurred. MAIN OUTCOME MEASURES: Visual field loss, ophthalmologic and nursing home costs, quality-adjusted life years (QALYs), cost per QALY gained, and cost per year of sight gained. Costs and QALYs were discounted to 2005 values using a 3% rate. RESULTS: Compared with no treatment and when including diagnostic assessment costs, the incremental cost-effectiveness of routine assessment and treatment was $46,000 per QALY gained, assuming conservative treatment efficacy, and $28,000 per QALY gained, assuming optimistic treatment efficacy. Compared with no treatment and when excluding diagnostic assessment costs, the incremental cost-effectiveness of routine assessment and treatment was $20,000 per QALY gained, assuming conservative treatment efficacy, and $11,000 per QALY gained, assuming optimistic treatment efficacy. The cost-effectiveness was most sensitive to the treatment costs and the value of QALY losses assigned to visual field losses. CONCLUSIONS: Glaucoma treatment was highly cost-effective when the costs of diagnostic assessments were excluded or when we assumed optimistic treatment efficacy. The cost was reasonable and in line with other health interventions even when diagnostic assessment costs were included and assuming conservative efficacy. FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or commercial interest in any materials discussed in this article.
Assuntos
Anti-Hipertensivos/economia , Técnicas de Diagnóstico Oftalmológico/economia , Cirurgia Filtrante/economia , Glaucoma de Ângulo Aberto , Custos de Cuidados de Saúde , Transtornos da Visão/prevenção & controle , Idoso , Idoso de 80 Anos ou mais , Anti-Hipertensivos/uso terapêutico , Ensaios Clínicos como Assunto , Simulação por Computador , Análise Custo-Benefício , Avaliação da Deficiência , Progressão da Doença , Seguimentos , Glaucoma de Ângulo Aberto/diagnóstico , Glaucoma de Ângulo Aberto/economia , Glaucoma de Ângulo Aberto/terapia , Pesquisa sobre Serviços de Saúde , Humanos , Incidência , Pessoa de Meia-Idade , Modelos Biológicos , Casas de Saúde/economia , Consultórios Médicos , Anos de Vida Ajustados por Qualidade de Vida , Estados Unidos , Transtornos da Visão/diagnóstico , Campos VisuaisRESUMO
PURPOSE: Primary open-angle glaucoma is a significant health-economic burden in both the United States and Europe that is likely to increase. This study compared treatment patterns and cost among patients with primary open-angle glaucoma in these locations. METHODS: Retrospective medical chart reviews were conducted in the United States (1990 to 2002) and Europe (1995 to 2003). A total sample of 151 US charts and 194 European charts was studied, and patients were assigned a baseline intraocular pressure (IOP) and baseline stage, using a 6-stage visual functional glaucoma staging algorithm. Resource utilization and direct costs were assessed by stage of disease using publicly available United States and European costs. Cox Proportional Hazards modeling were used to examine covariates predicting glaucoma surgery. Total cost was predicted, adjusting for covariates using Generalized Linear Models, with baseline stage as the independent variable. RESULTS: Glaucoma surgery requirement was highly associated with baseline disease stage and IOP increase before surgery in the United States and somewhat associated with these factors in Europe. Within both locations, baseline IOP was highly associated with glaucoma surgery requirement. Controlling for covariates, patients at higher baseline stages incurred greater costs in the United States (P=0.0017) and Europe (P=0.0715). Surgery and medication were also highly predictive of increased cost (P<0.0001). Cost of care differed greatly between the European countries, with costs lowest in Italy. CONCLUSIONS: Increases in annual cost were related to higher baseline IOP, higher baseline stage, medication, and surgery. Thus, significant potential savings and reductions in annual healthcare burden are possible if patients are diagnosed and treated at earlier stages of glaucoma.
Assuntos
Anti-Hipertensivos/economia , Efeitos Psicossociais da Doença , Cirurgia Filtrante/economia , Glaucoma de Ângulo Aberto/economia , Glaucoma de Ângulo Aberto/fisiopatologia , Custos de Cuidados de Saúde/estatística & dados numéricos , Idoso , Progressão da Doença , Economia Médica , Europa (Continente) , Feminino , Glaucoma de Ângulo Aberto/terapia , Recursos em Saúde/estatística & dados numéricos , Pesquisa sobre Serviços de Saúde , Humanos , Pressão Intraocular , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Resultado do Tratamento , Estados UnidosRESUMO
PURPOSE: To facilitate future glaucoma model development and to provide guidance for decision-makers evaluating them, we provide an overview of an innovative glaucoma model and highlight important modeling considerations. CONSIDERATIONS: The considerations that were addressed include: disease outcome that is both relevant and meaningful to current clinical practice; diversity in treatment options and practices; incorporation of therapy discontinuation; and consideration of the variability in patient response to treatment. MODEL SCOPE: A state-transition, Monte Carlo simulation model was developed to simulate the management and treatment of patients with glaucoma and/or ocular hypertension. The model examines strategies involving sequential use of up to 6 pharmacologic interventions. Transitions are based on the monthly probability that a patient is no longer "successfully maintained" on therapy, which can be a consequence of lack of intraocular pressure control, adverse events, lack of compliance, or lack of persistence. Outputs of the model include months on each treatment, frequency of therapy switches, days of intraocular pressure control, frequency of ophthalmologist visits, frequency of surgery, and glaucoma-related costs. The model allows the user to specify country-specific treatment strategies, survival on therapy, surgical rates, practice patterns, and costs. CONCEPT APPLICATION: The model presented offers insights into accommodating patient and clinician variability through the use of persistence distributions. It will facilitate future glaucoma model development and provide insight for decision-makers who must evaluate model-based analyses of the economic value of glaucoma interventions.
Assuntos
Glaucoma/economia , Glaucoma/terapia , Modelos Econômicos , Anti-Hipertensivos/economia , Anti-Hipertensivos/uso terapêutico , Análise Custo-Benefício , Atenção à Saúde/economia , Custos de Medicamentos , Cirurgia Filtrante/economia , Custos de Cuidados de Saúde , Pesquisa sobre Serviços de Saúde/economia , Humanos , Pressão Intraocular , Método de Monte Carlo , Hipertensão Ocular/economia , Hipertensão Ocular/terapia , Resultado do TratamentoRESUMO
OBJECTIVE: Glaucoma is generally managed by decreasing the intraocular pressure (IOP) to a level believed to prevent further damage to the optic disc and loss of visual field. This may be achieved medically or surgically. The objective of this pharmacoeconomic analysis was to investigate the 4-year costs of bimatoprost 0.03% (Lumigan) eye drops as an alternative to filtration surgery (FS) for glaucoma patients on maximum tolerable medical therapy (MTMT). RESEARCH DESIGN AND METHOD: A Markov model was designed using effectiveness and resource use data from a randomized clinical trial and expert statements (Delphi panel). The RCT covered 83 patients on MTMT. The Model compared bimatoprost with FS. In the bimatoprost model arm patients began treatment with bimatoprost. If target IOP (-20%) was not reached using medical therapy the patient proceeded with FS. In the FS model arm, FS was performed after the first ophthalmologist visit. Unit costs were obtained from an Italian chart and tariffs review (healthcare sector perspective). RESULTS: The RCT showed that 74.7% of the patients delayed the need for FS by 3 months. The Markov model forecasted that 64.2% of the patients could delay the need for FS by 1 year, and forecasted 34.0% could avoid FS after 4 years. The 4-year cost per patient in the bimatoprost and FS arms was E3438 and E4194, respectively (incremental costs of E755). The major cost drivers for the bimatoprost arm were patients who needed combination therapy or FS if the target IOP was not reached. In the FS arm, the major cost drives were the initial surgery costs and pressure-lowering medications used as add-on therapy after FS. CONCLUSIONS: The analysis shows that in a 4-year perspective bimatoprost is cheaper compared to FS. In addition, the postponement of FS associated with bimatoprost may have important implications for waiting list planning.
Assuntos
Cirurgia Filtrante , Glaucoma , Lipídeos , Idoso , Amidas , Bimatoprost , Cloprostenol/análogos & derivados , Análise Custo-Benefício , Cirurgia Filtrante/economia , Glaucoma/tratamento farmacológico , Glaucoma/economia , Glaucoma/cirurgia , Custos de Cuidados de Saúde , Humanos , Pressão Intraocular/efeitos dos fármacos , Pressão Intraocular/fisiologia , Itália , Lipídeos/economia , Lipídeos/farmacologia , Lipídeos/uso terapêutico , Cadeias de Markov , Soluções OftálmicasAssuntos
Anti-Hipertensivos/economia , Efeitos Psicossociais da Doença , Técnicas de Diagnóstico Oftalmológico/economia , Cirurgia Filtrante/economia , Glaucoma de Ângulo Fechado/economia , Custos de Cuidados de Saúde , Custos Hospitalares , Doença Aguda , Análise Custo-Benefício , Procedimentos Clínicos/economia , Economia Médica , Glaucoma de Ângulo Fechado/epidemiologia , Glaucoma de Ângulo Fechado/terapia , Humanos , Pressão Intraocular , Modelos Econômicos , Singapura/epidemiologiaRESUMO
AIM: To estimate the cost of management of acute primary angle closure glaucoma in Singapore. METHODS: In this cost analysis using retrospective data, the authors performed a MEDLINE search of published papers on acute primary angle closure glaucoma (APACG) in Singapore. Using information from published data, clinical management pathways were constructed and clinical outcomes identified. For each management path, costs of medical treatment, hospitalization, clinic charges, investigations, laser treatment and surgery were identified and accounted over a 5-year treatment period, using year 2002 rates. RESULTS: Given that, in Singapore, APACG affects 12.2 per 100,000 per year (95% confidence interval [CI], 10.5-13.9) in those aged 30 and older, each annual cohort would need to pay 261,741.78 US dollars (95%CI: US$225 310.90-298 265.10) or 287,560.26 US dollars (95%CI: 247,274.04-330,624.84 US dollars), if inclusive of cataract surgery, over 5 years after the episode of APACG. In this period, individuals would have to commit between 879.45 US dollars and 2576.39 US dollars, depending on the complexity of disease and accompanying cataract surgery. CONCLUSION: Acute primary angle closure glaucoma produces a substantial financial burden on society as well as on the individuals.
Assuntos
Anti-Hipertensivos/economia , Efeitos Psicossociais da Doença , Técnicas de Diagnóstico Oftalmológico/economia , Cirurgia Filtrante/economia , Glaucoma de Ângulo Fechado/economia , Custos de Cuidados de Saúde , Custos Hospitalares , Doença Aguda , Adulto , Análise Custo-Benefício , Procedimentos Clínicos/economia , Economia Médica , Glaucoma de Ângulo Fechado/epidemiologia , Glaucoma de Ângulo Fechado/terapia , Humanos , Pressão Intraocular , Modelos Econômicos , Estudos Retrospectivos , Singapura/epidemiologiaRESUMO
PURPOSE: The objective of this study was to investigate what treatment strategies prevail in different countries for patients newly diagnosed with primary open-angle glaucoma (POAG) or ocular hypertension (OH) only and initiated on treatment with beta-blockers, and to estimate the total direct cost of treatment for two years. In addition, differences in costs between and within the countries and the determinants of variations in costs across patients were examined. MATERIALS AND METHODS: The authors performed a retrospective medical record analysis in several academic and office-based study centers in Sweden and the United States. Standard costs for each resource item were determined and applied to all centers within the country. Differences in treatment costs within the countries are thus the effect of differences in treatment strategies, not of differences in prices. RESULTS: There was considerable variation between the centers of each country. Sweden had a higher number of surgical interventions, which may be explained by the fact that the Swedish cohort had a higher mean intraocular pressure (IOP) at baseline and a higher proportion of patients with definite POAG and exfoliation glaucoma. However, in both countries the mean IOP at study end was approximately 18 mm Hg. Total direct costs for two years were 15,119 SEK (US$2,160; $1US = 7 SEK) and $2,109, respectively. In a multiple regression analysis, the estimated effects of baseline IOP and of IOP change after treatment initiation on treatment costs were positively and negatively significant, respectively, in both countries. CONCLUSION: Despite differences in baseline diagnosis and in treatment strategies, mean IOP was decreased to 18 mm Hg in both countries. Baseline IOP was positively correlated with treatment costs, while the initial IOP-lowering effect of treatment was negatively correlated with two-year costs.